Consensus Amphastar Pharmaceuticals, Inc.

Stocks

AMPH

US03209R1032

Pharmaceuticals

Market Closed - Nasdaq 02:30:00 14/11/2026 am IST			5-day change	1st Jan Change
29.37 ^USD	+1.73%		+3.09%	+9.67%

07/11	Amphastar Pharmaceuticals, Inc., Q3 2026 Earnings Call, Nov 05, 2026
07/11	Amphastar Pharmaceuticals Insider Sold Shares Worth $814,669, According to a Recent SEC Filing	MT

Evolution of the Average Target: Amphastar Pharmaceuticals, Inc.

Evolution of the Target Price: Amphastar Pharmaceuticals, Inc.

Changes in Analyst Recommendations: Amphastar Pharmaceuticals, Inc.

64db1e089f0ac64389ae3be660bfe9.fVLX0xu4OcsEQ0LxjsDdlVWQSY47Q-QdLl-XFw-W02I.CRm_gW3QTvIzKQ-I7ITt4zeiOtFDDNBcRifOfEOloDU8DaS4I-tjgmsXNQ~f448590f23f00c061df8d6f56b97207a

Analysts' recommendations: Amphastar Pharmaceuticals, Inc.

18/08	Barclays Adjusts Price Target on Amphastar Pharmaceuticals to $23 From $20, Maintains Equalweight Rating	MT
29/06	BofA Securities Downgrades Amphastar Pharmaceuticals to Underperform From Neutral, Cuts Price Target to $20 From $25	MT
29/06	BofA Securities Downgrades Amphastar Pharmaceuticals to Underperform, $20 Price Target	MT
15/05	Amphastar Shares Fall After Wells Fargo Downgrade	MT
14/05	Wells Fargo Downgrades Amphastar Pharmaceuticals to Equalweight From Overweight, Adjusts PT to $19 From $30	MT
21/04	Jefferies Downgrades Amphastar Pharmaceuticals to Hold From Buy, Adjusts Price Target to $22 From $30	MT
07/01	BofA Securities Adjusts Price Target on Amphastar Pharmaceuticals to $30 From $31, Maintains Neutral Rating	MT
07/01	Biopharma Sector Enters 2026 With Clearer Outlook, Key Catalysts, BofA Says	MT
09/12	Barclays Initiates Amphastar Pharmaceuticals at Equalweight With $30 Price Target	MT
09/25/09	Ionis, Jazz Named Top Picks as US Biopharma Heads Into Steady Q3, BofA Says	MT
09/25/09	BofA Cuts Price Target on Amphastar Pharmaceuticals to $31 From $32	MT
12/25/12	Needham Upgrades Amphastar Pharmaceuticals to Buy From Hold, Price Target is $36	MT
12/25/12	JPMorgan Downgrades Amphastar Pharmaceuticals to Neutral From Overweight, Adjusts Price Target to $30 From $45	MT
21/25/21	BofA Adjusts Price Target on Amphastar Pharmaceuticals to $31 From $36	MT
04/25/04	Piper Sandler Downgrades Amphastar Pharmaceuticals to Neutral From Overweight, Adjusts Price Target to $36 From $66	MT
03/25/03	BofA Adjusts Price Target on Amphastar Pharmaceuticals to $44 From $46	MT
05/24/05	JPMorgan Initiates Amphastar Pharmaceuticals With Overweight Rating, Price Target is $60	MT
17/23/17	BofA Securities Initiates Amphastar Pharmaceuticals at Neutral Rating With $63 Price Target	MT
25/23/25	Jefferies Reinstates Buy Rating on Amphastar Pharmaceuticals With $70 Price Target	MT
17/23/17	Wells Fargo Adjusts Price Target on Amphastar Pharmaceuticals to $44 From $40, Maintains Equal-Weight Rating	MT
25/22/25	Piper Sandler Adjusts Amphastar Pharmaceuticals' Price Target to $40 From $43, Keeps Overweight Rating	MT
21/22/21	Jefferies Assumes Amphastar Pharmaceuticals at Buy with $36 Price Target	MT
29/22/29	Capital One Initiates Amphastar Pharmaceuticals at Overweight Rating With $44 Price Target	MT
11/22/11	Northland Adjusts Price Target on Amphastar Pharmaceuticals to $43 From $33, Keeps Outperform Rating	MT
08/22/08	Piper Sandler Raises Price Target for Amphastar Pharmaceuticals to $47 From $35, Maintains Overweight Rating	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	AMPHASTAR PHARMACEUTICALS, INC.					-16.58%
	ELI LILLY AND COMPANY					+1.38%
	JOHNSON & JOHNSON					-2.22%
	ABBVIE INC.					+5.69%
	ROCHE HOLDING AG					-2.05%
	MERCK & CO., INC.					+9.32%
	NOVARTIS AG					-3.71%
	ASTRAZENECA PLC					+16.57%
	AMGEN INC.					-7.27%
	GILEAD SCIENCES, INC.					+3.98%
	Average					+0.51%
	Weighted average by Cap.					+1.96%